Terms: = Breast cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Prognosis
278 results:
1. The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.
Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
[TBL] [Abstract] [Full Text] [Related]
2. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mtor pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract] [Full Text] [Related]
3. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mtor signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
4. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mtor signaling pathway in triple negative breast cancer.
Ou X; Tan Y; Xie J; Yuan J; Deng X; Shao R; Song C; Cao X; Xie X; He R; Li Y; Tang H
Drug Resist Updat; 2024 Mar; 73():101063. PubMed ID: 38335844
[TBL] [Abstract] [Full Text] [Related]
5. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mtor pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract] [Full Text] [Related]
6. The emerging role of noncoding RNAs in the PI3K/AKT/mtor signalling pathway in breast cancer.
Abu-Alghayth MH; Khan FR; Belali TM; Abalkhail A; Alshaghdali K; Nassar SA; Almoammar NE; Almasoudi HH; Hessien KBG; Aldossari MS; Binshaya AS
Pathol Res Pract; 2024 Mar; 255():155180. PubMed ID: 38330621
[TBL] [Abstract] [Full Text] [Related]
7. ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells.
Koh M; Lim H; Jin H; Kim M; Hong Y; Hwang YK; Woo Y; Kim ES; Kim SY; Kim KM; Lim HK; Jung J; Kang S; Park B; Lee HB; Han W; Lee MS; Moon A
Autophagy; 2024 Mar; 20(3):659-674. PubMed ID: 38290972
[TBL] [Abstract] [Full Text] [Related]
8. Biomimetic Nanomedicine Targeting Orchestrated Metabolism Coupled with Regulatory Factors to Disrupt the Metabolic Plasticity of breast cancer.
Meng L; Yang J; Gao Y; Cao Q; Jiang S; Xiao Y; Wang H; Liu W; Yuan A; Li Y; Huang H
ACS Nano; 2024 Feb; 18(5):4360-4375. PubMed ID: 38277483
[TBL] [Abstract] [Full Text] [Related]
9. Nanoemulsion potentiates the anti-cancer activity of Myricetin by effective inhibition of PI3K/AKT/mtor pathway in triple-negative breast cancer cells.
Sharma P; Chaturvedi S; Khan MA; Rai Y; Bhatt AN; Najmi AK; Akhtar M; Mishra AK
Med Oncol; 2024 Jan; 41(2):56. PubMed ID: 38218749
[TBL] [Abstract] [Full Text] [Related]
10. LINC01234 promoted malignant behaviors of breast cancer cells via hsa-miR-30c-2-3p/CCT4/mtor signaling pathway.
Tang C; Li C; Chen C; Chen T; Zhu J; Sun M; Wang P; Han C
Taiwan J Obstet Gynecol; 2024 Jan; 63(1):46-56. PubMed ID: 38216268
[TBL] [Abstract] [Full Text] [Related]
11. In Vitro and In Vivo Anti-cancer Activity of Lasiokaurin in a Triple-Negative breast cancer Model.
Lin J; Qu Z; Pu H; Shen LS; Yi X; Lin YS; Gong RH; Chen GQ; Chen S
Molecules; 2023 Nov; 28(23):. PubMed ID: 38067432
[TBL] [Abstract] [Full Text] [Related]
12. mtorC1 Mediates Biphasic Mechano-Response to Orchestrate Adhesion-Dependent Cell Growth and Anoikis Resistance.
Zhang C; Wang Y; Zhen Z; Li J; Su J; Wu C
Adv Sci (Weinh); 2024 Feb; 11(6):e2307206. PubMed ID: 38041494
[TBL] [Abstract] [Full Text] [Related]
13. Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles.
Zhang J; Zhou K; Lin J; Yao X; Ju D; Zeng X; Pang Z; Yang W
Biomaterials; 2023 Dec; 303():122395. PubMed ID: 37988899
[TBL] [Abstract] [Full Text] [Related]
14. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
Qiao L; Dong C; Jia W; Ma B
Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
[TBL] [Abstract] [Full Text] [Related]
15. Genetic Aspects of Conjunctival Melanoma: A Review.
Chang E; Demirci H; Demirci FY
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761808
[TBL] [Abstract] [Full Text] [Related]
16. Integrated network pharmacology, bioinformatics, and molecular docking to explore the mechanisms of berberine regulating autophagy in breast cancer.
Huang B; Wen G; Li R; Wu M; Zou Z
Medicine (Baltimore); 2023 Sep; 102(36):e35070. PubMed ID: 37682166
[TBL] [Abstract] [Full Text] [Related]
17. Synergistic effect of Dactolisib/Lys05 combination on autophagy in A549 cells.
Abdelwahab M; Saeed H; Elnikhely N; Nematalla H
Acta Biochim Pol; 2023 Sep; 70(3):615-622. PubMed ID: 37677845
[TBL] [Abstract] [Full Text] [Related]
18. Cytochrome b561 regulates iron metabolism by activating the Akt/mtor pathway to promote breast cancer Cells proliferation.
Zhou X; Guo X; Han J; Wang M; Liu Z; Ren D; Zhao J; Li Z
Exp Cell Res; 2023 Oct; 431(1):113760. PubMed ID: 37634562
[TBL] [Abstract] [Full Text] [Related]
19. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
[TBL] [Abstract] [Full Text] [Related]
20. Inetetamab in combination with rapamycin and chemotherapy for trastuzumab-treated metastatic human epidermal growth factor receptor 2-positive breast cancer with abnormal activation of PI3K/Akt/mtor pathway.
Wang A; Li C; Jiang Q; Jiang S
Cancer Rep (Hoboken); 2023 Sep; 6(9):e1864. PubMed ID: 37501598
[TBL] [Abstract] [Full Text] [Related]
[Next]
